Shan Yuping, Hou Feng, Wang Yan, Han Yi, Cui Zhumei, Yin Guangjie
Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Discov Oncol. 2025 Apr 29;16(1):633. doi: 10.1007/s12672-025-02500-8.
Metastatic breast cancer (BC) to the cervix is relatively rare among women with BC. Although the most common histopathological type of BC is invasive ductal carcinoma, invasive lobular carcinoma is more likely to metastasize to the female reproductive system due to its characteristic of the loss of E-cadherin. BC patients with metastasis to the cervix often exhibit no obvious clinical symptoms or may present with cervical-related symptoms, making early diagnosis challenging. CDK4/6 inhibitors, when combined with either aromatase inhibitors or fulvestrant, can enhance the prognosis for both premenopausal and postmenopausal women with recurrent ER-positive BC. We reported a patient with cervical metastasis of BC, who was ER-positive and HER2-negative. The patient received treatment with fulvestrant and abemaciclib after surgery for metastatic cervical cancer, achieving a progression-free survival of 31 months. We hope this case report will encourage more clinicians to prioritize gynecological examinations for patients with BC, particularly cervical cancer screening, in order to enhance the quality of life and prognosis for these individuals.
在乳腺癌女性患者中，转移性乳腺癌累及宫颈相对少见。虽然乳腺癌最常见的组织病理学类型是浸润性导管癌，但浸润性小叶癌因其E-钙黏蛋白缺失的特性，更易转移至女性生殖系统。发生宫颈转移的乳腺癌患者常无明显临床症状，或仅表现为与宫颈相关的症状，这使得早期诊断颇具挑战性。细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂与芳香化酶抑制剂或氟维司群联合使用时，可改善复发的雌激素受体（ER）阳性绝经前和绝经后乳腺癌女性患者的预后。我们报告了1例发生宫颈转移的ER阳性、人表皮生长因子受体2（HER2）阴性乳腺癌患者。该患者在转移性宫颈癌手术后接受了氟维司群和阿贝西利治疗，无进展生存期达31个月。我们希望本病例报告能鼓励更多临床医生重视乳腺癌患者的妇科检查，尤其是宫颈癌筛查，以提高这些患者的生活质量和预后。
